Projects at PCT

2018, Pilot study – Uppsala University

2019, Combination treatment study – Lund University

2019, Tumour treatment study – Uppsala University

2019, Combination treatment study – Uppsala University

2020, Combination treatment study – Beactica

2021, Side effects of treatment study – Karolinska Institute

2021, Combination treatment study – Beactica

2021, Flank tumour study – Uppsala University

2021, Tumour study – Karolinska Institute

2021, Preclinical drug development study – SciLifeLab DDD

2022, Glioma standard treatment pilot – Beactica/Uppsala University

2022, Combination treatment study – Beactica

2022, Flank xenograft treatment study – Karolinska Institute

2022, Tolerability study, brain tumor treatment – Uppsala University

2022, Hollow fiber evaluation – Uppsala University

2023, Flank xenograft treatment study – Uppsala University


Mainwaring OJ, Weishaupt H, Zhao M, et al. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nat Commun. 2023;14(1):1221. Published 2023 Mar 3. doi:10.1038/s41467-023-36847-9.

Borgenvik A, Holmberg KO, Bolin S, et al. Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma. Cancer Res. 2022;82(24):4586-4603. doi:10.1158/0008-5472.CAN-22-2108.

Berg TJ, Marques C, Pantazopoulou V, et al. The Irradiated Brain Microenvironment Supports Glioma Stemness and Survival via Astrocyte-Derived Transglutaminase 2. Cancer Res. 2021;81(8):2101-2115. doi:10.1158/0008-5472.CAN-20-1785.

Last modified: 2023-06-14